Immunomodulatory function of the tumor suppressor p53 in host immune response and the tumor microenvironment

International Journal of Molecular Sciences

Volumn 17, Issue 11, 2016, Pages

  Cui, Yan ^a   Guo, Gang ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Adaptive antitumor immunity; Immune suppression; Immunotherapy; Inflammation; Innate immunity; P53 inactivation; Tumor microenvironment; Tumor suppressor p53

Indexed keywords

APOPTOSIS INDUCING FACTOR; CHEMOKINE; CYTOKINE; PROTEIN P53; STAT PROTEIN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MDM2 PROTEIN, HUMAN; NUTLIN 3; PIPERAZINE DERIVATIVE; PROTEIN MDM2;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; CANCER ASSOCIATED FIBROBLAST; CARCINOGENESIS; GAIN OF FUNCTION MUTATION; GENE MUTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; NATURAL KILLER CELL; REVIEW; SENESCENCE; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; AGONISTS; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MUTATION; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOGENESIS; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; IMMUNE EVASION; MUTATION; NEOPLASMS; NF-KAPPA B; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84996565480     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17111942     Document Type: Review

References (140)

1. Vousden,K.H.; Lane,D.P. p53 in health and disease. Nat. Rev. 2007,8,275–283.
2. Levine,A.J. p53,the cellular gatekeeper for growth and division. Cell 1997,88,323–331.
3. Levine,A.J.; Oren,M. The first 30 years of p53: Growing ever more complex. Nat. Rev. Cancer 2009,9,749–758.
4. Olivier,M.; Hollstein,M.; Hainaut,P. TP53 mutations in human cancers: Origins,consequences,and clinical use. Cold Spring Harb. Perspect. Biol. 2010,2,a001008.
5. Bensaad,K.; Tsuruta,A.; Selak,M.A.; Vidal,M.N.; Nakano,K.; Bartrons,R.; Gottlieb,E.; Vousden,K.H. TIGAR,a p53-inducible regulator of glycolysis and apoptosis. Cell 2006,126,107–120.
6. Lane,D.; Levine,A. p53 Research: The past thirty years and the next thirty years. Cold Spring Harb. Perspect. Biol. 2010,2,a000893.
7. Vousden,K.H.; Prives,C. Blinded by the light: The growing complexity of p53. Cell 2009,137,413–431.
8. Menendez,D.; Inga,A.; Resnick,M.A. The expanding universe of p53 targets. Nat. Rev. Cancer 2009,9,724–737.
9. Aylon,Y.; Oren,M. New plays in the p53 theater. Curr. Opin. Genet. Dev. 2011,21,86–92.
10. Yi,L.; Lu,C.; Hu,W.; Sun,Y.; Levine,A.J. Multiple roles of p53-related pathways in somatic cell reprogramming and stem cell differentiation. Cancer Res. 2012,72,5635–5645.
11. Muller,P.A.; Caswell,P.T.; Doyle,B.; Iwanicki,M.P.; Tan,E.H.; Karim,S.; Lukashchuk,N.; Gillespie,D.A.; Ludwig,R.L.; Gosselin,P.; et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009,139,1327–1341.
12. Rivlin,N.; Koifman,G.; Rotter,V. p53 orchestrates between normal differentiation and cancer. Semin. Cancer Biol. 2015,32,10–17.
13. Hanahan,D.; Weinberg,R.A. Hallmarks of cancer: The next generation. Cell 2011,144,646–674.
14. Hussain,S.P.; Hollstein,M.H.; Harris,C.C. p53 tumor suppressor gene: At the crossroads of molecular carcinogenesis,molecular epidemiology,and human risk assessment. Ann. N. Y. Acad. Sci. 2000,919,79–85.
15. Hussain,S.P.; Amstad,P.; Raja,K.; Ambs,S.; Nagashima,M.; Bennett,W.P.; Shields,P.G.; Ham,A.J.; Swenberg,J.A.; Marrogi,A.J.; et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: A cancer-prone chronic inflammatory disease. Cancer Res. 2000,60,3333–3337.
16. Schetter,A.J.; Heegaard,N.H.; Harris,C.C. Inflammation and cancer: Interweaving microRNA,free radical,cytokine and p53 pathways. Carcinogenesis 2010,31,37–49.
17. Gudkov,A.V.; Gurova,K.V.; Komarova,E.A. Inflammation and p53: A tale of two stresses. Genes Cancer 2011,2,503–516.
18. Colotta,F.; Allavena,P.; Sica,A.; Garlanda,C.; Mantovani,A. Cancer-related inflammation,the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 2009,30,1073–1081.
19. Grivennikov,S.I.; Greten,F.R.; Karin,M. Immunity,inflammation,and cancer. Cell 2010,140,883–899.
20. DeLeo,A.B.; Whiteside,T.L. Development of multi-epitope vaccines targeting wild-type sequence p53 peptides. Expert Rev. Vaccines 2008,7,1031–1040.
21. Vermeij,R.; Leffers,N.; van der Burg,S.H.; Melief,C.J.; Daemen,T.; Nijman,H.W. Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies. J. Biomed. Biotechnol. 2011,2011,702146.
22. Chiappori,A.A.; Soliman,H.; Janssen,W.E.; Antonia,S.J.; Gabrilovich,D.I. INGN-225: A dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: Observed association between immune response and enhanced chemotherapy effect. Expert Opin. Biol. Ther. 2010,10,983–991.
23. Soussi,T. p53 alterations in human cancer: More questions than answers. Oncogene 2007,26,2145–2156.
24. Soussi,T.; Hamroun,D.; Hjortsberg,L.; Rubio-Nevado,J.M.; Fournier,J.L.; Beroud,C. MUT-TP53 2.0: A novel versatile matrix for statistical analysis of TP53 mutations in human cancer. Hum. Mutat. 2010,31,1020–1025.
25. Guo,G.; Marrero,L.; Rodriguez,P.; Del Valle,L.; Ochoa,A.; Cui,Y. Trp53 inactivation in the tumor microenvironment promotes tumor progression by expanding the immunosuppressive lymphoid-like stromal network. Cancer Res. 2013,73,1668–1675.
26. Zhang,S.; Zheng,M.; Kibe,R.; Huang,Y.; Marrero,L.; Warren,S.; Zieske,A.W.; Iwakuma,T.; Kolls,J.K.; Cui,Y. Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis. FASEB J. 2011,25,2387–2398.
27. Menendez,D.; Shatz,M.; Resnick,M.A. Interactions between the tumor suppressor p53 and immune responses. Curr. Opin. Oncol. 2013,25,85–92.
28. Komarova,E.A.; Krivokrysenko,V.; Wang,K.; Neznanov,N.; Chernov,M.V.; Komarov,P.G.; Brennan,M.L.; Golovkina,T.V.; Rokhlin,O.W.; Kuprash,D.V.; et al. p53 is a suppressor of inflammatory response in mice. FASEB J. 2005,19,1030–1032.
29. Martins,C.P.; Brown-Swigart,L.; Evan,G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006,127,1323–1334.
30. Ventura,A.; Kirsch,D.G.; McLaughlin,M.E.; Tuveson,D.A.; Grimm,J.; Lintault,L.; Newman,J.; Reczek,E.E.; Weissleder,R.; Jacks,T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007,445,661–665.
31. Xue,W.; Zender,L.; Miething,C.; Dickins,R.A.; Hernando,E.; Krizhanovsky,V.; Cordon-Cardo,C.; Lowe,S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007,445,656–660.
32. Kiaris,H.; Chatzistamou,I.; Trimis,G.; Frangou-Plemmenou,M.; Pafiti-Kondi,A.; Kalofoutis,A. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res. 2005,65,1627–1630.
33. Lujambio,A.; Akkari,L.; Simon,J.; Grace,D.; Tschaharganeh,D.F.; Bolden,J.E.; Zhao,Z.; Thapar,V.; Joyce,J.A.; Krizhanovsky,V.; et al. Non-cell-autonomous tumor suppression by p53. Cell 2013,153,449–460.
34. Coussens,L.M.; Werb,Z. Inflammation and cancer. Nature 2002,420,860–867.
35. Ostrand-Rosenberg,S.; Sinha,P. Myeloid-derived suppressor cells: Linking inflammation and cancer. J. Immunol. 2009,182,4499–4506.
36. Ben-Neriah,Y.; Karin,M. Inflammation meets cancer,with NF-κB as the matchmaker. Nat. Immunol. 2011,12,715–723.
37. Gajewski,T.F.; Meng,Y.; Blank,C.; Brown,I.; Kacha,A.; Kline,J.; Harlin,H. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 2006,213,131–145.
38. Kerkar,S.P.; Restifo,N.P. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res. 2012,72,3125–3130.
39. Swartz,M.A.; Iida,N.; Roberts,E.W.; Sangaletti,S.; Wong,M.H.; Yull,F.E.; Coussens,L.M.; DeClerck,Y.A. Tumor microenvironment complexity: Emerging roles in cancer therapy. Cancer Res. 2012,72,2473–2480.
40. Gabrilovich,D.I.; Nagaraj,S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009,9,162–174.
41. Gabrilovich,D.I.; Ostrand-Rosenberg,S.; Bronte,V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012,12,253–268.
42. Trinchieri,G. Cancer and inflammation: An old intuition with rapidly evolving new concepts. Annu. Rev. Immunol. 2012,30,677–706.
43. Karin,M.; Lawrence,T.; Nizet,V. Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer. Cell 2006,124,823–835.
44. Cooks,T.; Harris,C.C.; Oren,M. Caught in the cross fire: p53 in inflammation. Carcinogenesis 2014,35,1680–1690.
45. Tak,P.P.; Zvaifler,N.J.; Green,D.R.; Firestein,G.S. Rheumatoid arthritis and p53: How oxidative stress might alter the course of inflammatory diseases. Immunol. Today 2000,21,78–82.
46. Yamanishi,Y.; Boyle,D.L.; Rosengren,S.; Green,D.R.; Zvaifler,N.J.; Firestein,G.S. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc. Natl. Acad. Sci. USA 2002,99,10025–10030.
47. Tapinos,N.I.; Polihronis,M.; Moutsopoulos,H.M. Lymphoma development in Sjogren’s syndrome: Novel p53 mutations. Arthritis Rheum. 1999,42,1466–1472.
48. Staib,F.; Robles,A.I.; Varticovski,L.; Wang,X.W.; Zeeberg,B.R.; Sirotin,M.; Zhurkin,V.B.; Hofseth,L.J.; Hussain,S.P.; Weinstein,J.N.; et al. The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res. 2005,65,10255–10264.
49. Yamanishi,Y.; Boyle,D.L.; Pinkoski,M.J.; Mahboubi,A.; Lin,T.; Han,Z.; Zvaifler,N.J.; Green,D.R.; Firestein,G.S. Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am. J. Pathol. 2002,160,123–130.
50. Zheng,S.J.; Lamhamedi-Cherradi,S.E.; Wang,P.; Xu,L.; Chen,Y.H. Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes 2005,54,1423–1428.
51. Okuda,Y.; Okuda,M.; Bernard,C.C. Regulatory role of p53 in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2003,135,29–37.
52. Yao,Q.; Wang,S.; Glorioso,J.C.; Evans,C.H.; Robbins,P.D.; Ghivizzani,S.C.; Oligino,T.J. Gene transfer of p53 to arthritic joints stimulates synovial apoptosis and inhibits inflammation. Mol. Ther 2001,3,901–910.
53. Di Minin,G.; Bellazzo,A.; Dal Ferro,M.; Chiaruttini,G.; Nuzzo,S.; Bicciato,S.; Piazza,S.; Rami,D.; Bulla,R.; Sommaggio,R.; et al. Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Mol. Cell 2014,56,617–629.
54. Dibra,D.; Xia,X.; Mitra,A.; Cutrera,J.J.; Lozano,G.; Li,S. Mutant p53 in concert with an interleukin-27 receptor alpha deficiency causes spontaneous liver inflammation,fibrosis,and steatosis in mice. Hepatology 2016,63,1000–1012.
55. Schwitalla,S.; Ziegler,P.K.; Horst,D.; Becker,V.; Kerle,I.; Begus-Nahrmann,Y.; Lechel,A.; Rudolph,K.L.; Langer,R.; Slotta-Huspenina,J.; et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 2013,23,93–106.
56. Bhowmick,N.A.; Neilson,E.G.; Moses,H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004,432,332–337.
57. Orimo,A.; Gupta,P.B.; Sgroi,D.C.; Arenzana-Seisdedos,F.; Delaunay,T.; Naeem,R.; Carey,V.J.; Richardson,A.L.; Weinberg,R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005,121,335–348.
58. Orimo,A.; Weinberg,R.A. Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle 2006,5,1597–1601.
59. Shields,J.D.; Kourtis,I.C.; Tomei,A.A.; Roberts,J.M.; Swartz,M.A. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010,328,749–752.
60. Katakai,T.; Hara,T.; Sugai,M.; Gonda,H.; Shimizu,A. Lymph node fibroblastic reticular cells construct the stromal reticulum via contact with lymphocytes. J. Exp. Med. 2004,200,783–795.
61. Fletcher,A.L.; Malhotra,D.; Turley,S.J. Lymph node stroma broaden the peripheral tolerance paradigm. Trends Immunol. 2011,32,12–18.
62. Lee,J.W.; Epardaud,M.; Sun,J.; Becker,J.E.; Cheng,A.C.; Yonekura,A.R.; Heath,J.K.; Turley,S.J. Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self. Nat. Immunol. 2007,8,181–190.
63. Turley,S.J.; Fletcher,A.L.; Elpek,K.G. The stromal and haematopoietic antigen-presenting cells that reside in secondary lymphoid organs. Nat. Rev. Immunol. 2010,10,813–825.
64. Peduto,L.; Dulauroy,S.; Lochner,M.; Spath,G.F.; Morales,M.A.; Cumano,A.; Eberl,G. Inflammation recapitulates the ontogeny of lymphoid stromal cells. J. Immunol. 2009,182,5789–5799.
65. Hill,R.; Song,Y.; Cardiff,R.D.; van Dyke,T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005,123,1001–1011.
66. Patocs,A.; Zhang,L.; Xu,Y.; Weber,F.; Caldes,T.; Mutter,G.L.; Platzer,P.; Eng,C. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N. Engl. J. Med. 2007,357,2543–2551.
67. Yamanishi,Y.; Boyle,D.L.; Green,D.R.; Keystone,E.C.; Connor,A.; Zollman,S.; Firestein,G.S. p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritis. Arthritis Res. Ther. 2005,7,R12–R18.
68. Fukino,K.; Shen,L.; Patocs,A.; Mutter,G.L.; Eng,C. Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. JAMA 2007,297,2103–2111.
69. Orimo,A.; Weinberg,R.A. Heterogeneity of stromal fibroblasts in tumors. Cancer Biol. Ther. 2007,6,618–619.
70. Addadi,Y.; Moskovits,N.; Granot,D.; Lozano,G.; Carmi,Y.; Apte,R.N.; Neeman,M.; Oren,M. p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res. 2010,70,9650–9658.
71. Moskovits,N.; Kalinkovich,A.; Bar,J.; Lapidot,T.; Oren,M. p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res. 2006,66,10671–10676.
72. Mlecnik,B.; Bindea,G.; Kirilovsky,A.; Angell,H.K.; Obenauf,A.C.; Tosolini,M.; Church,S.E.; Maby,P.; Vasaturo,A.; Angelova,M. et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci. Transl. Med. 2016,8,327ra26.
73. Angell,H.; Galon,J. From the immune contexture to the Immunoscore: The role of prognostic and predictive immune markers in cancer. Curr. Opin. Immunol. 2013,25,261–267.
74. Mlecnik,B.; Bindea,G.; Angell,H.K.; Maby,P.; Angelova,M.; Tougeron,D.; Church,S.E.; Lafontaine,L.; Fischer,M.; Fredriksen,T.; et al. Integrative analyses of colorectal cancer show Immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 2016,44,698–711.
75. + T cells in patients with hepatocellular carcinoma: Comparison with Immunoscore. Oncotarget 2015,6,35602–35615.
76. Park,J.S.; Lim,M.A.; Cho,M.L.; Ryu,J.G.; Moon,Y.M.; Jhun,J.Y.; Byun,J.K.; Kim,E.K.; Hwang,S.Y.; Ju,J.H. et al. p53 controls autoimmune arthritis via STAT-mediated regulation of the Th17 cell/Treg cell balance in mice. Arthritis Rheuma. 2013,65,949–959.
77. Kawashima,H.; Takatori,H.; Suzuki,K.; Iwata,A.; Yokota,M.; Suto,A.; Minamino,T.; Hirose,K.; Nakajima,H. Tumor suppressor p53 inhibits systemic autoimmune diseases by inducing regulatory T cells. J. Immunol. 2013,191,3614–3623.
78. He,D.; Li,H.; Yusuf,N.; Elmets,C.A.; Li,J.; Mountz,J.D.; Xu,H. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J. Immunol. 2010,184,2281–2288.
79. Wang,L.; Yi,T.; Kortylewski,M.; Pardoll,D.M.; Zeng,D.; Yu,H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 2009,206,1457–1464.
80. Wang,L.; Yi,T.; Zhang,W.; Pardoll,D.M.; Yu,H. IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res. 2010,70,10112–10120.
81. Riley,T.; Sontag,E.; Chen,P.; Levine,A. Transcriptional control of human p53-regulated genes. Nat. Rev. 2008,9,402–412.
82. Levine,A.J. The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53. Virology 2009,384,285–293.
83. Havre,P.A.; Yuan,J.; Hedrick,L.; Cho,K.R.; Glazer,P.M. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res. 1995,55,4420–4424.
84. Jiang,D.; Srinivasan,A.; Lozano,G.; Robbins,P.D. SV40 T antigen abrogates p53-mediated transcriptional activity. Oncogene 1993,8,2805–2812.
85. Quaresma,J.A.; Yoshikawa,G.T.; Koyama,R.V.; Dias,G.A.; Fujihara,S.; Fuzii,H.T. HTLV-1,immune response and autoimmunity. Viruses 2015,8,5.
86. Ak,P.; Levine,A.J. p53 and NF-κB: Different strategies for responding to stress lead to a functional antagonism. FASEB J. 2010,24,3643–3652.
87. Kawauchi,K.; Araki,K.; Tobiume,K.; Tanaka,N. Activated p53 induces NF-κB DNA binding but suppresses its transcriptional activation. Biochem. Biophys. Res Commun. 2008,372,137–141.
88. Kawauchi,K.; Araki,K.; Tobiume,K.; Tanaka,N. p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation. Nat. Cell Biol. 2008,10,611–618.
89. Son,D.S.; Kabir,S.M.; Dong,Y.L.; Lee,E.; Adunyah,S.E. Inhibitory effect of tumor suppressor p53 on proinflammatory chemokine expression in ovarian cancer cells by reducing proteasomal degradation of IκB. PLoS ONE 2012,7,e51116.
90. Lowe,J.M.; Menendez,D.; Bushel,P.R.; Shatz,M.; Kirk,E.L.; Troester,M.A.; Garantziotis,S.; Fessler,M.B.; Resnick,M.A. p53 and NF-κB coregulate proinflammatory gene responses in human macrophages. Cancer Res. 2014,74,2182–2192.
91. Rodier,F.; Campisi,J. Four faces of cellular senescence. J. Cell Biol. 2011,192,547–556.
92. Davalos,A.R.; Kawahara,M.; Malhotra,G.K.; Schaum,N.; Huang,J.; Ved,U.; Beausejour,C.M.; Coppe,J.P.; Rodier,F.; Campisi,J. p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypes. J. Cell Biol. 2013,201,613–629.
93. Bollrath,J.; Greten,F.R. IKK/NF-κB and STAT3 pathways: Central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep. 2009,10,1314–1319.
94. Li,N.; Grivennikov,S.I.; Karin,M. The unholy trinity: Inflammation,cytokines,and STAT3 shape the cancer microenvironment. Cancer Cell 2011,19,429–431.
95. Yu,H.; Kortylewski,M.; Pardoll,D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007,7,41–51.
96. Yu,H.; Pardoll,D.; Jove,R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 2009,9,798–809.
97. Niu,G.; Wright,K.L.; Ma,Y.; Wright,G.M.; Huang,M.; Irby,R.; Briggs,J.; Karras,J.; Cress,W.D.; Pardoll,D. et al. Role of Stat3 in regulating p53 expression and function. Mol. Cell. Biol. 2005,25,7432–7440.
98. Hudson,J.D.; Shoaibi,M.A.; Maestro,R.; Carnero,A.; Hannon,G.J.; Beach,D.H. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 1999,190,1375–1382.
99. Bucala,R.; Donnelly,S.C. Macrophage migration inhibitory factor: A probable link between inflammation and cancer. Immunity 2007,26,281–285.
100. Mitchell,R.A.; Liao,H.; Chesney,J.; Fingerle-Rowson,G.; Baugh,J.; David,J.; Bucala,R. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response. Proc. Natl. Acad. Sci. USA 2002,99,345–350.
101. Harper,J.M.; Wilkinson,J.E.; Miller,R.A. Macrophage migration inhibitory factor-knockout mice are long lived and respond to caloric restriction. FASEB J. 2010,24,2436–2442.
102. Cortez,M.A.; Ivan,C.; Valdecanas,D.; Wang,X.; Peltier,H.J.; Ye,Y.; Araujo,L.; Carbone,D.P.; Shilo,K.; Giri,D.K. et al. PDL1 Regulation by p53 via miR-34. J. Natl. Cancer Inst. 2016,108,djv303.
103. Aloisi,F.; Pujol-Borrell,R. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. 2006,6,205–217.
104. Gajewski,T.F.; Schreiber,H.; Fu,Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013,14,1014–1022.
105. Pardoll,D. Cancer and the immune system: Basic concepts and targets for intervention. Semin. Oncol. 2015,42,523–538.
106. Mellman,I.; Coukos,G.; Dranoff,G. Cancer immunotherapy comes of age. Nature 2011,480,480–489.
107. Pitt,J.M.; Marabelle,A.; Eggermont,A.; Soria,J.C.; Kroemer,G.; Zitvogel,L. Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy. Ann. Oncol. 2016,27,1482–1492.
108. Burnette,B.C.; Liang,H.; Lee,Y.; Chlewicki,L.; Khodarev,N.N.; Weichselbaum,R.R.; Fu,Y.X.; Auh,S.L. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. 2011,71,2488–2496.
109. Kroemer,G.; Galluzzi,L.; Kepp,O.; Zitvogel,L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 2013,31,51–72.
110. Zitvogel,L.; Apetoh,L.; Ghiringhelli,F.; Andre,F.; Tesniere,A.; Kroemer,G. The anticancer immune response: Indispensable for therapeutic success? J. Clin. Investig. 2008,118,1991–2001.
111. Zitvogel,L.; Galluzzi,L.; Smyth,M.J.; Kroemer,G. Mechanism of action of conventional and targeted anticancer therapies: Reinstating immunosurveillance. Immunity 2013,39,74–88.
112. Ma,Y.; Adjemian,S.; Mattarollo,S.R.; Yamazaki,T.; Aymeric,L.; Yang,H.; Portela Catani,J.P.; Hannani,D.; Duret,H.; Steegh,K.; et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013,38,729–741.
113. Cekic,C.; Linden,J. Purinergic regulation of the immune system. Nat. Rev. Immunol. 2016,16,177–192.
114. Shatz,M.; Menendez,D.; Resnick,M.A. The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res. 2012,72,3948–3957.
115. Taura,M.; Eguma,A.; Suico,M.A.; Shuto,T.; Koga,T.; Komatsu,K.; Komune,T.; Sato,T.; Saya,H.; Li,J.D. et al. p53 regulates Toll-like receptor 3 expression and function in human epithelial cell lines. Mol. Cell. Biol. 2008,28,6557–6567.
116. Slatter,T.L.; Wilson,M.; Tang,C.; Campbell,H.G.; Ward,V.K.; Young,V.L.; Van Ly,D.; Fleming,N.I.; Braithwaite,A.W.; Baird,M.A. Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12. Oncoimmunology 2016,5,e1112941.
117. Gasser,S.; Orsulic,S.; Brown,E.J.; Raulet,D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005,436,1186–1190.
118. Gasser,S.; Raulet,D.H. The DNA damage response arouses the immune system. Cancer Res. 2006,66,3959–3962.
119. Li,H.; Lakshmikanth,T.; Garofalo,C.; Enge,M.; Spinnler,C.; Anichini,A.; Szekely,L.; Karre,K.; Carbone,E.; Selivanova,G. Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle 2011,10,3346–3358.
120. Textor,S.; Fiegler,N.; Arnold,A.; Porgador,A.; Hofmann,T.G.; Cerwenka,A. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res. 2011,71,5998–6009.
121. Iannello,A.; Thompson,T.W.; Ardolino,M.; Lowe,S.W.; Raulet,D.H. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J. Exp. Med. 2013,210,2057–2069.
122. Reed,J.C.; Alpers,J.D.; Nowell,P.C.; Hoover,R.G. Sequential expression of protooncogenes during lectin-stimulated mitogenesis of normal human lymphocytes. Proc. Natl. Acad. Sci. USA 1986,83,3982–3986.
123. Terada,N.; Lucas,J.J.; Gelfand,E.W. Differential regulation of the tumor suppressor molecules,retinoblastoma susceptibility gene product (Rb) and p53,during cell cycle progression of normal human T cells. J. Immunol. 1991,147,698–704.
124. Boehme,S.A.; Lenardo,M.J. TCR-mediated death of mature T lymphocytes occurs in the absence of p53. J. Immunol. 1996,156,4075–4078.
125. + T cell responses. Immunity 2014,40,681–691.
126. Cheok,C.F.; Verma,C.S.; Baselga,J.; Lane,D.P. Translating p53 into the clinic. Nat. Rev. Clin. Oncol. 2011,8,25–37.
127. Muller,P.A.; Vousden,K.H. Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell 2014,25,304–317.
128. Khoo,K.H.; Verma,C.S.; Lane,D.P. Drugging the p53 pathway: Understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 2014,13,217–236.
129. Kelly,R.M.; Goren,E.M.; Taylor,P.A.; Mueller,S.N.; Stefanski,H.E.; Osborn,M.J.; Scott,H.S.; Komarova,E.A.; Gudkov,A.V.; Hollander,G.A.; et al. Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation. Blood 2010,115,1088–1097.
130. Vassilev,L.T.; Vu,B.T.; Graves,B.; Carvajal,D.; Podlaski,F.; Filipovic,Z.; Kong,N.; Kammlott,U.; Lukacs,C.; Klein,C.; et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004,303,844–848.
131. Saha,M.N.; Micallef,J.; Qiu,L.; Chang,H. Pharmacological activation of the p53 pathway in haematological malignancies. J. Clin. Pathol. 2010,63,204–209.
132. Issaeva,N.; Bozko,P.; Enge,M.; Protopopova,M.; Verhoef,L.G.; Masucci,M.; Pramanik,A.; Selivanova,G. Small molecule RITA binds to p53,blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 2004,10,1321–1328.
133. Pflaum,J.; Schlosser,S.; Muller,M. p53 family and cellular stress responses in cancer. Front. Oncol. 2014,4,285.
134. Gasparini,C.; Tommasini,A.; Zauli,G. The MDM2 inhibitor Nutlin-3 modulates dendritic cell-induced T cell proliferation. Hum. Immunol. 2012,73,342–345.
135. Secchiero,P.; Toffoli,B.; Melloni,E.; Agnoletto,C.; Monasta,L.; Zauli,G. The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40. Acta Diabetol. 2013,50,899–906.
136. Bykov,V.J.; Issaeva,N.; Shilov,A.; Hultcrantz,M.; Pugacheva,E.; Chumakov,P.; Bergman,J.; Wiman,K.G.; Selivanova,G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 2002,8,282–288.
137. Stegh,A.H. Targeting the p53 signaling pathway in cancer therapy—The promises,challenges and perils. Expert Opin. Ther. Targets 2012,16,67–83.
138. Formenti,S.C.; Demaria,S. Combining radiotherapy and cancer immunotherapy: A paradigm shift. J. Natl. Cancer Inst. 2013,105,256–265.
139. Zitvogel,L.; Apetoh,L.; Ghiringhelli,F.; Kroemer,G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008,8,59–73.
140. Melero,I.; Arina,A.; Murillo,O.; Dubrot,J.; Alfaro,C.; Pérez-Gracia,J.L.; Bendandi,M.; Hervás-Stubbs,S. Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena. Clin. Cancer Res. 2006,12,2385–2389.